PGNX News and Press, Progenics Pharmaceuticals Inc.

Summary Today, we put the spotlight on Lantheus Holdings for the first time. The stock has been a big winner in 2022 thanks to the impressive growth racked up by recently launched imaging agent Pylarify. Can the good times continue for shareholders? An investment analysis foll...

Clovis, a "trading stock," has some shakiness in its fundamentals. Moreover, the shares tend to rise and fall for you to trade for short-term gains. Due to upcoming catalysts in June, Clovis is a trading stock that is about to embark on another bullish cycle. Despite being a tradi...

It has been nearly one year since I took a good look at Lantheus Holdings, but PYLARIFY's approval has forced me to reassess the ticker and my investment strategy. PYLARIFY has the potential to be a game-changer in prostate cancer diagnosis and improve patient outcomes. The company ha...

Lantheus Holdings (LNTH) , the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals (PGNX) entered into a stock purchase agreement to sell its Puerto Rico radiopharmacy and positron emission tomography ((PET)) manufacturing facility ((PMF)) to PharmaLo...

Lantheus Holdings (LNTH), which merged with Progenics Pharmaceuticals (PGNX) in June, announces the filing of a U.S. marketing application seeking approval of PyL (18-F DCFPyL), a prostate-specific membrane antigen ((PSMA))-targeted positron emission tomography ((PET)) imaging agent for ...

The second half of the year could provide some solid wins for investors in the cancer therapeutics market. In recent years, Wall Street has flocked to many of these biotechnology companies because of their potential to deliver cutting-edge treatments and generate long-term returns. As cancer ...

Biopharma Dynavax Technologies (NASDAQ: DVAX) is one of many companies racing to develop a COVID-19 vaccine. Like many coronavirus-focused companies, Dynavax has seen its shares rise on the ongoing concern related to the pandemic -- in its case, by 50% year to date. While investors may co...

Merger activity decreased last week with one new deal announced, two deals closing, and one deal called off. After terminating deals with AcelRx Pharmaceuticals (ACRX) and Melinta Therapeutics (MLNT), Tetraphase Pharmaceuticals (TTPH) agreed to be acquired by La Jolla Pharmaceutical Company ...

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced that it...

Merger activity decreased last week with two new deals announced, and one deal closing. One of the two new deals announced last week was on our list of potential deals and the other one was a "going private" transaction. According to Reuters, Australian antitrust regulators expressed conc...